TP53 and ovarian carcinoma: However, despite TP53 mutation in the NIH-OVCAR3 cells (Figure 1A), they were 11-fold more resistant to the ATRi, VE-821, compared to a panel of 12 ovarian cancer cell lines (Figure 2A,D).